株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

眼科用薬の世界市場:症状(ドライアイ・緑内障・感染症・炎症・アレルギー・網膜疾患)、種類、剤形、技術、流通チャネル、治療クラス、地域別

Ophthalmic Drugs Market by Indication, Type, Dosage Form, Technology, Distribution Channel, and Therapeutic Class - Global Opportunity Analysis and Industry Forecast, 2017-2023

発行 Allied Market Research 商品コード 586570
出版日 ページ情報 英文 351 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
眼科用薬の世界市場:症状(ドライアイ・緑内障・感染症・炎症・アレルギー・網膜疾患)、種類、剤形、技術、流通チャネル、治療クラス、地域別 Ophthalmic Drugs Market by Indication, Type, Dosage Form, Technology, Distribution Channel, and Therapeutic Class - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日: 2017年11月01日 ページ情報: 英文 351 Pages
概要

当レポートでは、眼科用薬の世界市場を調査し、市場の概要、症状・種類・剤形・技術・流通チャネル・治療クラス・地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

  • 調査概要
  • 主な利点
  • 市場区分
  • 調査手法

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • ファイブフォース分析
  • 市場シェアの分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会

第4章 眼科用薬の世界市場:症状別

  • 市場概要
  • ドライアイ
  • 緑内症
  • 感染症・炎症・アレルギー
  • 網膜疾患
  • その他

第5章 眼科用薬の世界市場:種類別

  • 市場概要
  • 医療用医薬品
  • 一般用医薬品(OTC薬)

第6章 眼科用薬の世界市場:流通チャネル別

  • 市場概要
  • 病院内薬局
  • ドラッグストア
  • オンライン薬局
  • その他

第7章 眼科用薬の世界市場:剤形別

  • 市場概要
  • 点眼液
  • 眼軟膏
  • 内服薬
  • ドラッグデリバリー
  • その他

第8章 眼科用薬の世界市場:治療クラス別

  • 市場概要
  • 抗炎症薬
  • 抗感染症薬
  • 緑内障治療薬
  • 抗アレルギー薬

第9章 眼科用薬の世界市場:技術別

  • 市場概要
  • 生物学的製剤
  • 細胞治療
  • 遺伝子治療
  • 低分子技術
  • ドラッグデリバリー
  • その他

第10章 眼科用薬の世界市場:地域別

  • 市場概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ・中東・アフリカ
    • ブラジル
    • 南アフリカ
    • トルコ
    • サウジアラビア
    • その他

第11章 企業プロファイル

  • ALLERGAN PLC
  • F. HOFFMANN-LA ROCHE AG
  • NOVARTIS AG
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • 参天製薬
  • SHIRE PLC
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VALEANT PHARMACEUTICAL INTERNATIONAL, INC.

図表リスト

図表

List of Tables

  • TABLE 1. NOVARTIS OPHTHALMOLOGIC PIPELINE PORTFOLIO, JULY 2011
  • TABLE 2. GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 3. OPHTHALMIC DRUGS MARKET FOR DRY EYE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 4. OPHTHALMIC DRUGS MARKET FOR GLAUCOMA, BY REGION, 2016-2023 ($MILLION)
  • TABLE 5. OPHTHALMIC DRUGS MARKET FOR INFECTION/INFLAMMATION/ALLERGY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 6. OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 7. OPHTHALMIC DRUGS MARKET FOR RETINAL DISORDERS, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 8. OPHTHALMIC DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016-2023 ($MILLION)
  • TABLE 9. OPHTHALMIC DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2016-2023 ($MILLION)
  • TABLE 10. OPHTHALMIC DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 11. OPHTHALMIC DRUGS MARKET FOR OTHER, BY REGION, 2016-2023 ($MILLION)
  • TABLE 12. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 14. PRESCRIPTION OPHTHALMIC DRUGS OFFERED BY BAUSCH + LOMB
  • TABLE 15. PRESCRIPTION OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 16. OPHTHALMIC DRUGS AVAILABLE OVER THE COUNTER FOR THE TREATMENT OF DRY EYE
  • TABLE 17. OVER-THE-COUNTER OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 19. OPHTHALMIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 20. OPHTHALMIC DRUGS MARKET FOR DRUG STORES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 21. OPHTHALMIC DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 22. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 24. OPHTHALMIC DRUGS ADMINISTERED IN LIQUID FORMS
  • TABLE 25. LIQUID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 26. OPHTHALMIC DRUGS ADMINISTERED IN SEMISOLID FORMS
  • TABLE 27. SEMISOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 28. VARIOUS TYPES OF SOLID OPHTHALMIC DRUG FORMS
  • TABLE 29. SOLID OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 30. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 31. OTHER OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 33. OPHTHALMIC DRUGS MARKET FOR ANTI-INFLAMMATORY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 34. OPHTHALMIC DRUGS MARKET FOR ANTI-INFECTIVE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 35. OPHTHALMIC DRUGS MARKET FOR ANTI-GLAUCOMA, BY REGION, 2016-2023 ($MILLION)
  • TABLE 36. OPHTHALMIC DRUGS MARKET FOR ANTI-ALLERGY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 37. GLOBAL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 38. FDA-APPROVED OCULAR BIOLOGICS
  • TABLE 39. OPHTHALMIC DRUGS MARKET FOR BIOLOGICS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 40. OPHTHALMIC DRUGS MARKET FOR CELL THERAPY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 41. OPHTHALMIC DRUGS MARKET FOR GENE THERAPY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 42. OPHTHALMIC DRUGS MARKET FOR SMALL MOLECULE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 43. OPHTHALMIC DRUGS MARKET FOR DRUG DELIVERY, BY REGION, 2016-2023 ($MILLION)
  • TABLE 44. OPHTHALMIC DRUGS MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 45. OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 46. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 47. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 48. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 49. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 50. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 51. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 52. NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 53. U.S. OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 54. U.S. OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 55. U.S. OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 56. U.S. OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 57. U.S. OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 58. U.S. OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 59. CANADA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 60. CANADA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 61. CANADA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 62. CANADA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 63. CANADA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 64. CANADA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 65. MEXICO OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 66. MEXICO OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 67. MEXICO OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 68. MEXICO OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 69. MEXICO OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 70. MEXICO OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 71. EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 72. EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 73. EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 74. EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 75. EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 76. EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 77. EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 78. GERMANY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 79. GERMANY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 80. GERMANY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 81. GERMANY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 82. GERMANY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 83. GERMANY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 84. FRANCE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 85. FRANCE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 86. FRANCE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 87. FRANCE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 88. FRANCE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 89. FRANCE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 90. UK OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 91. UK OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 92. UK OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 93. UK OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 94. UK OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 95. UK OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 96. ITALY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 97. ITALY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 98. ITALY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 99. ITALY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 100. ITALY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 101. ITALY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 102. SPAIN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 103. SPAIN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 104. SPAIN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 105. SPAIN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 106. SPAIN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 107. SPAIN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 108. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 109. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 110. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 111. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 112. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 113. REST OF EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 114. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 115. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 116. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 117. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 118. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 119. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 120. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 121. JAPAN OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 122. JAPAN OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 123. JAPAN OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 124. JAPAN OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 125. JAPAN OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 126. JAPAN OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 127. CHINA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 128. CHINA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 129. CHINA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 130. CHINA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 131. CHINA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 132. CHINA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 133. INDIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 134. INDIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 135. INDIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 136. INDIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 137. INDIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 138. INDIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 139. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 140. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 141. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 142. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 143. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 144. AUSTRALIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 145. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 146. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 147. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 148. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 149. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 150. SOUTH KOREA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 151. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 152. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 153. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 154. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 155. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 156. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 157. LAMEA OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 158. LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 159. LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 160. LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 161. LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 162. LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 163. LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 164. BRAZIL OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 165. BRAZIL OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 166. BRAZIL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 167. BRAZIL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 168. BRAZIL OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 169. BRAZIL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 170. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 171. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 172. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 173. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 174. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 175. SOUTH AFRICA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 176. TURKEY OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 177. TURKEY OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 178. TURKEY OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 179. TURKEY OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 180. TURKEY OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 181. TURKEY OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 182. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 183. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 184. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 185. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 186. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 187. SAUDI ARABIA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 188. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 189. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 190. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2016-2023 ($MILLION)
  • TABLE 191. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016-2023 ($MILLION)
  • TABLE 192. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 193. REST OF LAMEA OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2016-2023 ($MILLION)
  • TABLE 194. ALLERGAN: COMPANY SNAPSHOT
  • TABLE 195. ALLERGEN: OPERATING SEGMENTS
  • TABLE 196. ALLERGAN: PRODUCT PORTFOLIO
  • TABLE 197. ROCHE: COMPANY SNAPSHOT
  • TABLE 198. ROCHE: OPERATING SEGMENT
  • TABLE 199. ROCHE: PRODUCT PORTFOLIO
  • TABLE 200. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 201. NOVARTIS: OPERATING SEGMENTS
  • TABLE 202. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 203. PFIZER: COMPANY SNAPSHOT
  • TABLE 204. PFIZER: OPERATING SEGMENTS
  • TABLE 205. PFIZER: PRODUCT PORTFOLIO
  • TABLE 206. REGENERON: COMPANY SNAPSHOT
  • TABLE 207. REGENERON: PRODUCT PORTFOLIO
  • TABLE 208. SANTEN PHARMACEUTICAL: COMPANY SNAPSHOT
  • TABLE 209. SANTEN PHARMACEUTICAL: OPERATING SEGMENTS
  • TABLE 210. SANTEN PHARMACEUTICAL: PRODUCT PORTFOLIO
  • TABLE 211. SHIRE: COMPANY SNAPSHOT
  • TABLE 212. SHIRE: PRODUCT PORTFOLIO
  • TABLE 213. SUN PHARMA: COMPANY SNAPSHOT
  • TABLE 214. SUN PHARMA: OPERATING SEGMENTS
  • TABLE 215. SUN PHARMA: PRODUCT PORTFOLIO
  • TABLE 216. TEVA: COMPANY SNAPSHOT
  • TABLE 217. TEVA: OPERATING SEGMENTS
  • TABLE 218. TEVA: PRODUCT PORTFOLIO
  • TABLE 219. VALEANT: COMPANY SNAPSHOT
  • TABLE 220. VALEANT: OPERATING SEGMENTS
  • TABLE 221. VALEANT: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 1. GLOBAL OPHTHALMIC DRUGS MARKET SNAPSHOT, 2016-2023
  • FIGURE 2. OPHTHALMIC DRUGS MARKET, BY REGION, 2016-2023
  • FIGURE 3. MARKET SEGMENTATION
  • FIGURE 4. TOP INVESTMENT POCKETS
  • FIGURE 5. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
  • FIGURE 6. TOTAL NUMBER OF STRATEGIES
  • FIGURE 7. TOP WINNING STRATEGIES: NATURE AND COMPANY
  • FIGURE 8. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 9. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 10. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 11. HIGH THREAT OF SUBSTITUTION
  • FIGURE 12. MODERATE COMPETITIVE RIVALRY
  • FIGURE 13. MARKET SHARE ANALYSIS, 2016
  • FIGURE 14. DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 15. PREVALENT CASES OF AMD IN THE U.S., 2010
  • FIGURE 16. GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, 2016
  • FIGURE 17. ALLERGAN: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 18. ALLERGAN: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 19. ROCHE: NET-SALES, 2014-2016 ($MILLION)
  • FIGURE 20. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 21. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 22. NOVARTIS: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 23. NOVARTIS: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 24. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 25. ALCON: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 26. ALCON: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 27. PFIZER: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 28. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 29. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 30. REGENERON: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 31. SANTEN PHARMACEUTICAL: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 32. SANTEN PHARMACEUTICAL: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 33. SANTEN PHARMACEUTICAL: REVENUE SHARE BY PRODUCT CATEGORY, 2017 (%)
  • FIGURE 34. SANTEN PHARMACEUTICAL: REVENUE SHARE BY GEOGRAPHY, 2017(%)
  • FIGURE 35. SHIRE: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 36. SHIRE: REVENUE SHARE BY PRODUCT CATEGORY, 2016 (%)
  • FIGURE 37. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 38. SUN PHARMA: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 39. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 40. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 41. TEVA: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 42. TEVA: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 43. TEVA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 44. VALEANT: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 45. VALEANT: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 46. VALEANT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
目次
Product Code: LI 17310

Ophthalmic drugs are preparations used for the treatment of eye diseases and disorders such as cataract, glaucoma, color blindness, diabetic macular edema, CMV retinitis, and age-related macular degeneration. The ophthalmic drugs market is witnessing significant growth, due to increase in prevalence of eye disorders and rise in use of combination therapies for treatment of ophthalmic disorders, especially glaucoma. Combination therapies have various advantages over traditional medication such improvement in patient compliance and efficacy. Moreover, surge in prevalence of ophthalmic disorders, rise in geriatric population globally, and change in demographics fuel the ophthalmic drugs market growth. The global ophthalmic drugs market was valued at $29,613 million in 2016, and is expected to reach $42,663 million by 2023, registering a CAGR of 5.3% from 2017 to 2023.

The ophthalmic drugs market is segmented based on indication, type, distribution channel, dosage form, technology, therapeutic class, and geography. Depending on indication, the market is divided into dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. On the basis of type, the market is bifurcated into prescription drugs and over-the-counter drugs. By distribution channel, it is categorized into hospital pharmacies, online pharmacies, drug stores, and others. According to dosage form, it is classified into liquid ophthalmic drug forms, semisolid ophthalmic drug forms, solid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. As per technology, the market is segmented into biologics, cell therapy, gene therapy, drug delivery, small molecule, and others. Based on therapeutic class, it is classified into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, and anti-allergy drugs. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

As per ophthalmic drugs market analysis, in the recent years, Asia-Pacific reported significant growth in the ophthalmic drugs market, owing to steady increase in the prevalence of glaucoma in the Asian population. In addition, increase in the number of people suffering from primary angle-closure glaucoma in Japan, China, and South Korea supplement this growth further.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global ophthalmic drugs market with the current trends and future estimations to elucidate the imminent investment pockets.
  • Comprehensive analysis of the factors that drive and restrict the market growth is provided.
  • Comprehensive quantitative analysis of the industry is provided from 2016 to 2023 to assist stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps in understanding the trends in types and technologies globally.
  • Key players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

By Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
  • Wet Age-related Macular Degeneration
  • Dry Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Others
  • Others

By Type

  • Prescription Drugs
  • Over-the-Counter Drugs

By Dosage Form

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms

By Technology

  • Biologics
  • Cell Therapy
  • Gene Therapy
  • Drug Delivery
  • Small Molecule
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

By Therapeutic Class

  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammatory
  • Anti-allergy

By Geography

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Turkey
  • Saudi Arabia
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Santen Pharmaceutical Co., Ltd.
  • Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.)
  • Shire Plc
  • Alcon (Novartis)
  • Genentech, Inc.
  • Allergan, Plc
  • Sun Pharmaceutical Industries Limited
  • Actavis Generics (Teva Pharmaceutical Industries Ltd.)
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • The other players in the value chain include (profiles not included in the report)
  • Abbott Medical Optics, Inc.
  • Carl-Zeiss AG
  • Ellex Medical Lasers Ltd.
  • Essilor International S.A.
  • Hoya Corporation
  • Insight Vision Inc.
  • Nidek Co. Ltd.
  • Novagali Pharma S A
  • Topcon Corporation
  • Ziemer Ophthalmic Systems AG

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PORTERS FIVE FORCES ANALYSIS
  • 3.4. MARKET SHARE ANALYSIS, 2016
  • 3.5. MARKET DYNAMICS
    • 3.5.1. Drivers
      • 3.5.1.1. Increase in focus of key players to develop combination therapies for the treatment of ophthalmic disorders
      • 3.5.1.2. Rise in prevalence of ophthalmic disorders worldwide
      • 3.5.1.3. Change in the demographics across the globe
    • 3.5.2. Restraints
      • 3.5.2.1. Longer timelines required for the development of ophthalmic drugs
      • 3.5.2.2. Risk of side effects associated with ophthalmic drugs
    • 3.5.3. Opportunity
      • 3.5.3.1. Increase in investment by market players in the emerging economies

CHAPTER 4 OPHTHALMIC DRUGS MARKET, BY INDICATION

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. DRY EYE
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. GLAUCOMA
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. INFECTION/INFLAMMATION/ALLERGY
    • 4.4.1. Key market trends
    • 4.4.2. Growth factors and opportunities
    • 4.4.3. Market size and forecast
  • 4.5. RETINAL DISORDERS
    • 4.5.1. Key market trends
    • 4.5.2. Growth factors and opportunities
    • 4.5.3. Market size and forecast
    • 4.5.4. Wet age-related macular degeneration
      • 4.5.4.1. Market size and forecast
    • 4.5.5. Dry age-related macular degeneration
      • 4.5.5.1. Market size and forecast
    • 4.5.6. Diabetic retinopathy
      • 4.5.6.1. Market size and forecast
    • 4.5.7. Others
      • 4.5.7.1. Market size and forecast
  • 4.6. OTHERS
    • 4.6.1. Key market trends
    • 4.6.2. Growth factors and opportunities
    • 4.6.3. Market size and forecast

CHAPTER 5 OPHTHALMIC DRUGS MARKET, BY TYPE

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. PRESCRIPTION DRUGS
    • 5.2.1. Market size and forecast
  • 5.3. OVER-THE-COUNTER DRUGS
    • 5.3.1. Market size and forecast

CHAPTER 6 OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. HOSPITAL PHARMACIES
    • 6.2.1. Market size and forecast
  • 6.3. DRUG STORES
    • 6.3.1. Market size and forecast
  • 6.4. ONLINE PHARMACIES
    • 6.4.1. Market size and forecast
  • 6.5. OTHERS
    • 6.5.1. Market size and forecast

CHAPTER 7 OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM

  • 7.1. OVERVIEW
    • 7.1.1. Market size and forecast
  • 7.2. LIQUID OPHTHALMIC DRUG FORMS
    • 7.2.1. Market size and forecast
  • 7.3. SEMISOLID OPHTHALMIC DRUG FORMS
    • 7.3.1. Market size and forecast
  • 7.4. SOLID OPHTHALMIC DRUG FORMS
    • 7.4.1. Market size and forecast
  • 7.5. MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
    • 7.5.1. Market size and forecast
  • 7.6. OTHER OPHTHALMIC DRUG FORMS
    • 7.6.1. Market size and forecast

CHAPTER 8 OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS

  • 8.1. OVERVIEW
    • 8.1.1. Market size and forecast
  • 8.2. ANTI-INFLAMMATORY
    • 8.2.1. Market size and forecast
    • 8.2.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
    • 8.2.3. Steroids
  • 8.3. ANTI-INFECTIVE
    • 8.3.1. Market size and forecast
    • 8.3.2. Antifungal drugs
    • 8.3.3. Antibacterial drugs
    • 8.3.4. Others
  • 8.4. ANTI-GLAUCOMA
    • 8.4.1. Market size and forecast
    • 8.4.2. Beta blockers
    • 8.4.3. Prostaglandin analogs
    • 8.4.4. Others
  • 8.5. ANTI-ALLERGY
    • 8.5.1. Market size and forecast

CHAPTER 9 OPHTHALMIC DRUGS MARKET, BY TECHNOLOGY

  • 9.1. OVERVIEW
    • 9.1.1. Market size and forecast
  • 9.2. BIOLOGICS
    • 9.2.1. Market size and forecast
  • 9.3. CELL THERAPY
    • 9.3.1. Market size and forecast
  • 9.4. GENE THERAPY
    • 9.4.1. Market size and forecast
  • 9.5. SMALL MOLECULE
    • 9.5.1. Market size and forecast
  • 9.6. DRUG DELIVERY
    • 9.6.1. Market size and forecast
  • 9.7. OTHERS
    • 9.7.1. Market size and forecast

CHAPTER 10 OPHTHALMIC DRUGS MARKET, BY REGION

  • 10.1. OVERVIEW
    • 10.1.1. Market size and forecast
  • 10.2. NORTH AMERICA
    • 10.2.1. Key market trends
    • 10.2.2. Key growth factors and opportunities
    • 10.2.3. Market size and forecast, by country
    • 10.2.4. Market size and forecast, by indication
    • 10.2.5. Market size and forecast, by type
    • 10.2.6. Market size and forecast, by technology
    • 10.2.7. Market size and forecast, by distribution channel
    • 10.2.8. Market size and forecast, by dosage form
    • 10.2.9. Market size and forecast, by therapeutic class
      • 10.2.9.1. U.S., by indication
      • 10.2.9.2. U.S., by type
      • 10.2.9.3. U.S., by distribution channel
      • 10.2.9.4. U.S., by dosage form
      • 10.2.9.5. U.S., by technology
      • 10.2.9.6. U.S., by therapeutic class
      • 10.2.9.7. Canada, by indication
      • 10.2.9.8. Canada, by type
      • 10.2.9.9. Canada, by distribution channel
      • 10.2.9.10. Canada, by dosage form
      • 10.2.9.11. Canada, by technology
      • 10.2.9.12. Canada, by therapeutic class
      • 10.2.9.13. Mexico, by indication
      • 10.2.9.14. Mexico, by type
      • 10.2.9.15. Mexico, by distribution channel
      • 10.2.9.16. Mexico, by dosage form
      • 10.2.9.17. Mexico, by technology
      • 10.2.9.18. Mexico, by therapeutic class
  • 10.3. EUROPE
    • 10.3.1. Key market trends
    • 10.3.2. Key growth factors and opportunities
    • 10.3.3. Europe Market size and forecast, by country
    • 10.3.4. Market size and forecast, by indication
    • 10.3.5. Market size and forecast, by type
    • 10.3.6. Market size and forecast, by technology
    • 10.3.7. Market size and forecast, by distribution channel
    • 10.3.8. Market size and forecast, by dosage form
    • 10.3.9. Market size and forecast, by therapeutic class
      • 10.3.9.1. Germany, by indication
      • 10.3.9.2. Germany, by type
      • 10.3.9.3. Germany, by distribution channel
      • 10.3.9.4. Germany, by dosage form
      • 10.3.9.5. Germany, by technology
      • 10.3.9.6. Germany, by therapeutic class
      • 10.3.9.7. France, by indication
      • 10.3.9.8. France, by type
      • 10.3.9.9. France, by distribution channel
      • 10.3.9.10. France, by dosage form
      • 10.3.9.11. France, by technology
      • 10.3.9.12. France, by therapeutic class
      • 10.3.9.13. UK, by indication
      • 10.3.9.14. UK, by type
      • 10.3.9.15. UK, by distribution channel
      • 10.3.9.16. UK, by dosage form
      • 10.3.9.17. UK, by technology
      • 10.3.9.18. UK, by therapeutic class
      • 10.3.9.19. Italy, by indication
      • 10.3.9.20. Italy, by type
      • 10.3.9.21. Italy, by distribution channel
      • 10.3.9.22. Italy, by dosage form
      • 10.3.9.23. Italy, by technology
      • 10.3.9.24. Italy, by therapeutic class
      • 10.3.9.25. Spain, by indication
      • 10.3.9.26. Spain, by type
      • 10.3.9.27. Spain, by distribution channel
      • 10.3.9.28. Spain, by dosage form
      • 10.3.9.29. Spain, by technology
      • 10.3.9.30. Spain, by therapeutic class
      • 10.3.9.31. Rest of Europe, by indication
      • 10.3.9.32. Rest of Europe, by type
      • 10.3.9.33. Rest of Europe, by distribution channel
      • 10.3.9.34. Rest of Europe, by dosage form
      • 10.3.9.35. Rest of Europe, by technology
      • 10.3.9.36. Rest of Europe, by therapeutic class
  • 10.4. ASIA-PACIFIC
    • 10.4.1. Key market trends
    • 10.4.2. Key growth factors and opportunities
    • 10.4.3. Asia-Pacific Market size and forecast, by country
    • 10.4.4. Market size and forecast, by indication
    • 10.4.5. Market size and forecast, by type
    • 10.4.6. Market size and forecast, by technology
    • 10.4.7. Market size and forecast, by distribution channel
    • 10.4.8. Market size and forecast, by dosage form
    • 10.4.9. Market size and forecast, by therapeutic class
      • 10.4.9.1. Japan, by indication
      • 10.4.9.2. Japan, by type
      • 10.4.9.3. Japan, by distribution channel
      • 10.4.9.4. Japan, by dosage form
      • 10.4.9.5. Japan, by technology
      • 10.4.9.6. Japan, by therapeutic class
      • 10.4.9.7. China, by indication
      • 10.4.9.8. China, by type
      • 10.4.9.9. China, by distribution channel
      • 10.4.9.10. China, by dosage form
      • 10.4.9.11. China, by technology
      • 10.4.9.12. China, by therapeutic class
      • 10.4.9.13. India, by indication
      • 10.4.9.14. India, by type
      • 10.4.9.15. India, by distribution channel
      • 10.4.9.16. India, by dosage form
      • 10.4.9.17. India, by technology
      • 10.4.9.18. India, by therapeutic class
      • 10.4.9.19. Australia, by indication
      • 10.4.9.20. Australia, by type
      • 10.4.9.21. Australia, by distribution channel
      • 10.4.9.22. Australia, by dosage form
      • 10.4.9.23. Australia, by technology
      • 10.4.9.24. Australia, by therapeutic class
      • 10.4.9.25. South Korea, by indication
      • 10.4.9.26. South Korea, by type
      • 10.4.9.27. South Korea, by distribution channel
      • 10.4.9.28. South Korea, by dosage form
      • 10.4.9.29. South Korea, by technology
      • 10.4.9.30. South Korea, by therapeutic class
      • 10.4.9.31. Rest of Asia-Pacific, by indication
      • 10.4.9.32. Rest of Asia-Pacific, by type
      • 10.4.9.33. Rest of Asia-Pacific, by distribution channel
      • 10.4.9.34. Rest of Asia-Pacific, by dosage form
      • 10.4.9.35. Rest of Asia-Pacific, by technology
      • 10.4.9.36. Rest of Asia-Pacific, by therapeutic class
  • 10.5. LAMEA
    • 10.5.1. Key market trends
    • 10.5.2. Key growth factors and opportunities
    • 10.5.3. LAMEA Market size and forecast, by country
    • 10.5.4. Market size and forecast, by indication
    • 10.5.5. Market size and forecast, by type
    • 10.5.6. Market size and forecast, by technology
    • 10.5.7. Market size and forecast, by distribution channel
    • 10.5.8. Market size and forecast, by dosage form
    • 10.5.9. Market size and forecast, by therapeutic class
      • 10.5.9.1. Brazil, by indication
      • 10.5.9.2. Brazil, by type
      • 10.5.9.3. Brazil, by distribution channel
      • 10.5.9.4. Brazil, by dosage form
      • 10.5.9.5. Brazil, by technology
      • 10.5.9.6. Brazil, by therapeutic class
      • 10.5.9.7. South Africa, by indication
      • 10.5.9.8. South Africa, by type
      • 10.5.9.9. South Africa, by distribution channel
      • 10.5.9.10. South Africa, by dosage form
      • 10.5.9.11. South Africa, by technology
      • 10.5.9.12. South Africa, by therapeutic class
      • 10.5.9.13. Turkey, by indication
      • 10.5.9.14. Turkey, by type
      • 10.5.9.15. Turkey, by distribution channel
      • 10.5.9.16. Turkey, by dosage form
      • 10.5.9.17. Turkey, by technology
      • 10.5.9.18. Turkey, by therapeutic class
      • 10.5.9.19. Saudi Arabia, by indication
      • 10.5.9.20. Saudi Arabia, by type
      • 10.5.9.21. Saudi Arabia, by distribution channel
      • 10.5.9.22. Saudi Arabia, by dosage form
      • 10.5.9.23. Saudi Arabia, by technology
      • 10.5.9.24. Saudi Arabia, by therapeutic class
      • 10.5.9.25. Rest of LAMEA, by indication
      • 10.5.9.26. Rest of LAMEA, by type
      • 10.5.9.27. Rest of LAMEA, by distribution channel
      • 10.5.9.28. Rest of LAMEA, by dosage form
      • 10.5.9.29. Rest of LAMEA, by technology
      • 10.5.9.30. Rest of LAMEA, by therapeutic class

CHAPTER 11 COMPANY PROFILES

  • 11.1. ALLERGAN PLC
    • 11.1.1. Company overview
    • 11.1.2. Company snapshot
    • 11.1.3. Operating business segments
    • 11.1.4. Product portfolio
    • 11.1.5. Business performance
    • 11.1.6. Key strategic moves and developments
  • 11.2. F. HOFFMANN-LA ROCHE AG (GENENTECH, INC.)
    • 11.2.1. Company overview
    • 11.2.2. Company snapshot
    • 11.2.3. Operating business segments
    • 11.2.4. Product portfolio
    • 11.2.5. Business performance
    • 11.2.6. Key strategic moves and developments
  • 11.3. NOVARTIS AG (ALCON-A DIVISION OF NOVARTIS)
    • 11.3.1. Company overview
    • 11.3.2. Company snapshot
    • 11.3.3. Operating business segments
    • 11.3.4. Product portfolio
    • 11.3.5. Business performance
    • 11.3.6. Key strategic moves and developments
  • 11.4. PFIZER INC.
    • 11.4.1. Company overview
    • 11.4.2. Company snapshot
    • 11.4.3. Operating business segments
    • 11.4.4. Product portfolio
    • 11.4.5. Business performance
    • 11.4.6. Key strategic moves and developments
  • 11.5. REGENERON PHARMACEUTICALS INC.
    • 11.5.1. Company overview
    • 11.5.2. Company snapshot
    • 11.5.3. Operating business segments
    • 11.5.4. Product portfolio
    • 11.5.5. Business performance
    • 11.5.6. Key strategic moves and developments
  • 11.6. SANTEN PHARMACEUTICAL CO., LTD.
    • 11.6.1. Company overview
    • 11.6.2. Company snapshot
    • 11.6.3. Operating business segments
    • 11.6.4. Product portfolio
    • 11.6.5. Business performance
    • 11.6.6. Key strategic moves and developments
  • 11.7. SHIRE PLC
    • 11.7.1. Company overview
    • 11.7.2. Company snapshot
    • 11.7.3. Operating business segments
    • 11.7.4. Product portfolio
    • 11.7.5. Business performance
    • 11.7.6. Key strategic moves and developments
  • 11.8. SUN PHARMACEUTICAL INDUSTRIES LIMITED
    • 11.8.1. Company overview
    • 11.8.2. Company snapshot
    • 11.8.3. Operating business segments
    • 11.8.4. Product portfolio
    • 11.8.5. Business performance
    • 11.8.6. Key strategic moves and developments
  • 11.9. TEVA PHARMACEUTICAL INDUSTRIES LTD.( ACTAVIS GENERICS)
    • 11.9.1. Company overview
    • 11.9.2. Company snapshot
    • 11.9.3. Operating business segments
    • 11.9.4. Product portfolio
    • 11.9.5. Business performance
    • 11.9.6. Key strategic moves and developments
  • 11.10. VALEANT PHARMACEUTICAL INTERNATIONAL, INC. (BAUSCH & LOMB INC.)
    • 11.10.1. Company overview
    • 11.10.2. Company snapshot
    • 11.10.3. Operating business segments
    • 11.10.4. Product portfolio
    • 11.10.5. Business performance
    • 11.10.6. Key strategic moves and developments
Back to Top